Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (226)	1/4/1999 2:22:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 804

V1: For last three years CELG have thin and troubled cash position. It was to long to bring Thal on market (than many though). Nonetheless, many though that it will never reach market and now are betting that will not sell at all. New CEO, Jackson manage company in this period well and turned thing around. Now it is time to straight cash position, by more convertible (at higher price than last one) and/or by partnering one or more of their three programs. If they can survive next two Q (I mean without significant dilution), and if growth of the T revenue reach expectation (my early projection was ~50 MM, now are at 80-100 MM, but if certain development materialize sale can reach 150-200 MM) than in 3/4 Q T revenue should be sufficient to support clinical and research expense. Today CELG cash position is not that troubled like 6 months ago, imo. Also Jackson prove that it can solve problematic situation. So, I am more optimistic now that before. Miljenko